Guizhounli Pharmaceutical Co (SHSE:603439) Long-Term Debt: ¥150 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603439 Guizhou Sanli Pharmaceutical Co Ltd SHSE:603439
91 GF Score
Price ¥12.12
GF Value ¥15.99
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Guizhounli Pharmaceutical Co Long-Term Debt?

Guizhounli Pharmaceutical Co SHSE:603439 -2.34% 91 Long-Term Debt is ¥150 Mil as of Mar. 2026. GuruFocus rates SHSE:603439 with a GF Score™ of 91/100 and a GF Value™ of ¥15.99 (Modestly Undervalued). The stock has 10 warning signs investors should review.

Guizhounli Pharmaceutical Co's Long-Term Debt for the quarter that ended in Mar. 2026 was ¥150 Mil.

Guizhounli Pharmaceutical Co's quarterly Long-Term Debt declined from Sep. 2025 (¥179 Mil) to Dec. 2025 (¥150 Mil) and declined from Dec. 2025 (¥150 Mil) to Mar. 2026 (¥150 Mil).

Guizhounli Pharmaceutical Co's annual Long-Term Debt declined from Dec. 2023 (¥254 Mil) to Dec. 2024 (¥209 Mil) and declined from Dec. 2024 (¥209 Mil) to Dec. 2025 (¥150 Mil).

Guizhounli Pharmaceutical Co  (SHSE:603439) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Guizhounli Pharmaceutical Co Long-Term Debt Related Terms

Guizhounli Pharmaceutical Co Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Guizhounli Pharmaceutical Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guizhounli Pharmaceutical Co Long-Term Debt Chart

Guizhounli Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 254.15 209.30 149.72

Guizhounli Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 209.30 179.40 179.40 149.72 149.50
SHSE:603439
91GF Score
Guizhou Sanli Pharmaceutical Co Ltd SHSE:603439
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ¥150 Mil mean?
Guizhounli Pharmaceutical Co (SHSE:603439) has a Long-Term Debt of ¥150 Mil as of Mar. 2026.
Is Guizhounli Pharmaceutical Co's Long-Term Debt too high?
Guizhounli Pharmaceutical Co's current Long-Term Debt is ¥150 Mil. Overall, Guizhounli Pharmaceutical Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guizhounli Pharmaceutical Co's Long-Term Debt compare to ZTS?
Guizhounli Pharmaceutical Co's Long-Term Debt of ¥150 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Guizhounli Pharmaceutical Co's current Long-Term Debt is ¥150 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guizhounli Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co (SHSE:603439) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥15.99, compared to a current price of ¥12.12 — trading 24.2% below its estimated fair value. The current Long-Term Debt is ¥150 Mil. Guizhounli Pharmaceutical Co's overall GF Score™ is 91/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Guizhounli Pharmaceutical Co (SHSE:603439), the current Long-Term Debt is ¥150 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guizhounli Pharmaceutical Co (SHSE:603439) Overvalued in 2026?

Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥12.12 is trading 24.2% below its estimated GF Value™ of ¥15.99. GuruFocus considers Guizhounli Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:603439:

  • Long-Term Debt: ¥150 Mil
  • GF Value™: ¥15.99 vs. price of ¥12.12 (24.2% below fair value)
  • GF Score™: 91/100 with 10 warning signs

No single metric tells the full story. See the SHSE:603439 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guizhounli Pharmaceutical Co Business Description

Address Xiayun Industrial Park, Pingba District, Guizhou Province, Anshun, CHN, 561000
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
91GF Score

Get the complete analysis for SHSE:603439

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥12.12
Price
¥15.99
GF Value